EXOPHARM LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0275 AUD | +10.00% |
|
-.--% | -.--% |
| 26/02 | Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| 2023 | Exopharm to Cut CEO Role Amid Cost Reductions | MT |
| Sales 2022 | 4.21M 2.75M 229M | Sales 2023 | 3.39M 2.22M 185M | Capitalization | 3.52M 2.3M 192M |
|---|---|---|---|---|---|
| Net income 2022 | -10M -6.54M -545M | Net income 2023 | -7M -4.58M -381M | EV / Sales 2022 | 4.6 x |
| Net cash position 2022 | 1.1M 722K 60.15M | Net cash position 2023 | 109K 71.46K 5.96M | EV / Sales 2023 | 1 x |
| P/E ratio 2022 |
-2.03
x | P/E ratio 2023 |
-0.22
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 24.71% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +10.00% |
1 year
0.01
0.04
3 years
0.011.94
5 years
0.012.50
10 years
0.012.50
| Managers | Title | Age | Since |
|---|---|---|---|
Ian Dixon
FOU | Founder | - | 01/13/01 |
Alison Mew
PRN | Corporate Officer/Principal | 66 | 15/20/15 |
David Franks
SEC | Corporate Secretary | 53 | 30/21/30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Davies
CHM | Chairman | - | 22/23/22 |
Ian Dixon
FOU | Founder | - | 01/13/01 |
Clarke Barlow
BRD | Director/Board Member | 43 | 22/23/22 |
Tryptamine Therapeutics Limited, formerly Exopharm Limited, is an Australia-based company involved in advancing genetic medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and non-viral drug delivery. The Company invests in biopharmaceutical drug development. The Company is engaged in exosome technology and holds a portfolio of intellectual property and know-how related to exosomes and the manufacture of exosomes. The Companyâs exosome technologies solve the needs for the success of exosome medicines, LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies. The Company is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome delivery for their own products.
Calendar
28/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 3.15M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- EX1 Stock
